The Newark Star-Ledger today reports:
“Merck & Co. said it will end development of the experimental drug preladenant for Parkinson’s disease because a preliminary review of the data from late-stage clinical trials suggests it doesn’t work.”
The full story here:
nj.com/business/index.ssf/20 … nt_of.html
If only Merck had been equally enlightened in the mid-'90s, while developing Vioxx and Propecia.